Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:

‍

Swiss-American pharmaceutical company, Novartis, announced it plans to sell Sandoz, its generic pharmaceuticals unit. The strategy is intended to strengthen the focus on its patented medicines. (PharmaLive)

Wired examines how polio transmission has reemerged in the United States and elsewhere after a long absence, looking at the history of the vaccine, and how it was deployed.

The Mayo Clinic, based in Rochester, Minnesota, announced a collaboration with National Resilience Inc. Their aim is to deliver novel therapeutics, targeting exact tissues. Julie Allickson, Ph.D., of Mayo Clinic's Center for Regenerative Medicine, said, "This nexus of entrepreneurs, startups and industry experts will help position Mayo Clinic as an authority in regenerative biotherapeutics." (Mayo Clinic Center for Regenerative Medicine)

The Duke Human Vaccine Institute at Duke University, in North Carolina, tours it facilities and discusses its plans to create vaccines to combat future flu pandemics, with the support of the Collaborative Influenza Vaccine Innovation Centers (CIVICs). (Duke University School of Medicine)

Worldwide Clinical Trials, Inc. has opened a new 15,000-square-foot lab in Austin, Texas. The multi-million dollar facility is named the Bioanalytical Center of Excellence. (Worldwide in the News)

The CNS Summit 2022 will be held on November 17–20, in Boca Raton, Florida. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. Team Judi will be there!

We also hope to see you this September 13-14, in Boston, for DPHARM: Disruptive Innovations to Advance Clinical Trials, walking distance from our North End headquarters.

‍

‍

‍

‍

Our Culture

“We are small enough that we are nimble, so we can prioritize quickly, yet also of significant size that we allocate resources where needed. We truly do a lot. This is my dream job. Judi allows me to have a bigger impact. And we do great work.”
‍
                            –Jess, Program Manager

‍

‍

‍

About Judi

Judi is on a mission to empower the ecosystems that drive clinical trial success by improving their workflows. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.

‍